Novartis holds sales growth at 5% through 2031 and raises peak-sales estimates for three drugs
Key Facts
On November 19, Novartis said net sales are expected to grow at a 5% compound annual rate at constant currencies from 2026 to 2031, targeting a return of its core operating income margin to 40% or more by 2029. The new sales target is at the lower end of its previous range of 5% to 6% annually through 2030. The company's shares fell 2% in early trading on November 19, according to Reuters. The company said its outlook takes long-term growth prospects into account as it seeks to expand its portfolio of medicines capable of offsetting declines in products facing the loss of patent protection. It said its medium-term targets do not assume large acquisitions.
Novartis, meanwhile, raised peak-sales estimates for three drugs on the market. It increased its estimate for Kesimpta from $6 billion to $8 billion, while the estimate for each of Scemblix and Leqvio rose from $4 billion to $5 billion. The changes reflect the company's higher expectations for the commercial potential of these treatments and provide support for sales growth in the coming years. The company places nine marketed assets in a category with peak-sales potential of between $3 billion and $10 billion. It said in its presentation that it has more than 35 readouts that could enable regulatory filings through 2031.
The outlook is also underpinned by a broad development pipeline: Novartis says its portfolio includes more than 30 high-value potential therapeutic assets across four major therapeutic areas and three advanced technology platforms. More than 20 of these assets are in registration or Phase II or III, while more than 10 are in Phase I or about to enter it. The company links this research pipeline to its medium-term growth opportunities, with several clinical readouts approaching that could open the way to regulatory filings. But the breadth of the pipeline alone does not guarantee drug success or a conversion into sales, making late-stage trial results a factor in the company's ability to meet its targets. Its presentation noted that more than 35 potential readouts through 2031 could enable regulatory filings.
The growth plan faces expected erosion in sales of key drugs from generic competition. The company's chart shows the impact of this competition through 2031, focusing on Cosentyx, Entresto, Jakavi, Tafinlar, Mekinist and Ilaris, alongside growth from marketed drugs and the development portfolio. According to Reuters, breast-cancer drug Kisqali and immunology drug Cosentyx will face cheaper alternatives by 2031. Entresto is already facing strong generic competition, and the company expects to lose $4 billion in sales from it during 2026. Visible Alpha estimated that combined sales of Kisqali and Cosentyx will reach $16.6 billion in 2030, before declining to $14 billion in 2031 as competition approaches.
The forecast update comes as the company also faces risks tied to drug development. Reuters said failures in several late-stage clinical studies during the year contributed to a $2.2 billion write-off in the third quarter of 2026. Those failures included a trial of del-desiran for muscle weakness, intensifying investor scrutiny of Chief Executive Vas Narasimhan's acquisition-led strategy. In this context, Narasimhan said the medium-term targets do not include large acquisitions and that contributions from mergers and acquisitions and business development are expected to remain consistent with the company's past activity. This balances the plan's reliance on product and pipeline growth against the constraints imposed by competition and trial risks.
The Meet Novartis Management event was held in London on November 19, 2026. Its agenda included a presentation by the chief executive and a question-and-answer session at 08:00 GMT, followed by breakout sessions at 09:45 and a panel on artificial intelligence at 14:30. The event gave the company an opportunity to present its targets and portfolio to investors and answer their questions about growth and its sources. The new sales guidance sets a path through 2031, but is narrower than the previous range, which extended through 2030. Achieving it will depend on the ability of newer drugs and assets in development to offset declines in products facing cheaper competition. The company also set a return of its core operating income margin to 40% or more by 2029 among its financial targets.